Novartis (NVS) Q3 2026 Earnings Call Transcript

Novartis (NVS) reported Q3 2026 earnings, highlighting growth in key drugs: Kisqali (37%), Kesimpta (22%), Pluvicto (20%), Leqvio (63%), and Semblix (67%). Kisqali led in EBC market share, while Kesimpta gained MS market share. Pluvicto saw early uptake in PSMA edition launch. Leqvio outperformed in the lipid-lowering market. Semblix neared market leadership in first-line treatments. Cosentyx grew 9% in constant currencies. Rhapsido showed strong launch momentum with additional approvals.

Original reporting
Published Oct 27, 2026, 4:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 5:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Novartis (NVS) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$NVSBullishMed
01

Why it matters

The disclosed growth rates and new data readouts provide fresh insight into the company's pipeline and market share gains.

02

Market read

The earnings details offer actionable insight for traders focusing on pharma equities.

03

What to watch

Potential pricing pressures or reimbursement challenges in emerging markets.

Relevance 7/10Novelty 6/10Timing: post‑earnings today

Background

Novartis presented its Q3 2026 earnings call, highlighting growth in Kisqali, Pluvicto, Kesimpta, Leqvio, and other products.

Company-level read

Ticker impact

$NVSBullishHigh confidence
Context

The transcript discloses Q3 2026 performance metrics for Novartis, including double‑digit growth in multiple product lines and new data readouts, which were not previously public.

Expected impact

likely upward pressure as investors price in robust product uptake and upcoming data readouts

Evidence & confidence

Growth percentages and new clinical data indicate positive earnings outlook, supporting a bullish bias.

Market effects

Positive signals for oncology and cardiovascular drug sectors may lift peers.

U.S. and European markets may see modest gains in pharma stocks.

Novartis' global footprint means the news resonates across major markets.

Counterpoint

If growth slows in later quarters, the current optimism could be premature.

Key entities

  • Novartis

    Swiss‑based pharmaceutical giant reporting Q3 2026 results.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$NVSMedAI 8/10

Novartis Trims Growth Target at Annual Management Day, Shares Slide

Novartis reduced its mid-term sales growth outlook to 5% annually from 2026-2031, down from a prior 5-6% range. Shares fell 3% on the news. The revision follows patent expirations and clinical trial failures, including a $2.2B writedown. Despite this, Novartis raised peak sales forecasts for three key drugs: Kesimpta, Scemblix, and Leqvio. The company expects growth beyond 2031 from internally developed medicines, with 10 in late-stage development.

$NVSMed

Novartis trims medium-term growth target, shares fall

Novartis reduced its annual sales growth target to 5% through 2031, down from a previous range of 5%-6%. Shares fell 3.3% after the announcement, which came amid patent expirations and clinical trial setbacks. The company expects growth from existing drugs like Kesimpta, Scemblix, and Leqvio, with no large acquisitions planned. Analysts anticipate growth slowing post-2030 due to competition for key drugs.